rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ENLV
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Enlivex reports positive 12-month knee osteoarthritis trial data
      Nov 2Investing.comENLV
      Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response
      Nov 2Yahoo FinanceENLV
      Enlivex enrolls 135 patients in phase 2b knee osteoarthritis trial
      Oct 28Investing.comENLV
      Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
      Oct 28Yahoo FinanceENLV
      Enlivex receives Nasdaq delisting notice over bid price
      Oct 27Investing.comENLV
      Enlivex announces 1-for-16 reverse stock split effective Oct. 27
      Oct 22Investing.comENLV
      Enlivex cuts workforce 60% to focus on phase 2b trial
      Oct 19Investing.comENLV
      Enlivex Calls October 14 Extraordinary Meeting to Approve 1-for-16 Reverse Share Split

      Detailed price information for Enlivex Ltd (ENLV-Q) from The Globe and Mail including charting and trades.

      Sep 30The Globe and MailENLV
      Enlivex terminates securities deal with Rain Foundation
      Sep 22Investing.comENLV
      Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

      Enlivex Ltd. (ENLV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

      Sep 1Yahoo FinanceENLV
      12 Health Care Stocks Moving In Thursday's After-Market Session - Aethlon Medical (NASDAQ:AEMD), Modular

      Gainers Aethlon Medical (NASDAQ:AEMD) stock rose 50.7% to $3.27 during Thursday's after-market session. The market value of their outstanding shares is at $1.6 million. Modular Medical (NASDAQ:MODD) stock rose

      Aug 27BenzingaAEMDENLVMODD

      This is the newest page. Registered accounts read further back.